Brokerages Set Krystal Biotech Inc (KRYS) Price Target at $33.67
Krystal Biotech Inc (NASDAQ:KRYS) has been assigned a consensus rating of “Buy” from the six research firms that are covering the stock, MarketBeat.com reports. Two investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. The average 1 year price objective among brokers that have issued ratings on the stock in the last year is $33.67.
A number of research analysts have commented on the company. Zacks Investment Research lowered Krystal Biotech from a “buy” rating to a “hold” rating in a report on Saturday, September 1st. LADENBURG THALM/SH SH set a $38.00 price objective on Krystal Biotech and gave the company a “buy” rating in a report on Thursday, July 19th. Chardan Capital assumed coverage on Krystal Biotech in a report on Thursday, June 28th. They issued a “buy” rating and a $35.00 price objective on the stock. William Blair assumed coverage on Krystal Biotech in a report on Monday, August 6th. They issued a “buy” rating on the stock. Finally, Cantor Fitzgerald assumed coverage on Krystal Biotech in a report on Monday. They issued an “overweight” rating and a $28.00 price objective on the stock.
KRYS opened at $17.91 on Monday. Krystal Biotech has a 1-year low of $8.03 and a 1-year high of $21.17.
A number of hedge funds and other institutional investors have recently modified their holdings of KRYS. Acadian Asset Management LLC grew its holdings in shares of Krystal Biotech by 552.2% during the 2nd quarter. Acadian Asset Management LLC now owns 12,202 shares of the company’s stock worth $182,000 after purchasing an additional 10,331 shares in the last quarter. BlackRock Inc. grew its holdings in shares of Krystal Biotech by 75.4% during the 2nd quarter. BlackRock Inc. now owns 13,040 shares of the company’s stock worth $194,000 after purchasing an additional 5,607 shares in the last quarter. Finally, Millennium Management LLC acquired a new stake in shares of Krystal Biotech during the 4th quarter worth $266,000. 23.07% of the stock is currently owned by hedge funds and other institutional investors.
About Krystal Biotech
Krystal Biotech, Inc, a gene therapy company, develops and commercializes pharmaceutical products for patients suffering from dermatological diseases in the United States. The company's lead product candidate is KB103, which is in preclinical development to treat dystrophic epidermolysis bullosa, a genetic disease.
Further Reading: How to Calculate Compound Annual Growth Rate (CAGR)
Receive News & Ratings for Krystal Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Krystal Biotech and related companies with MarketBeat.com's FREE daily email newsletter.